{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:19:58Z","timestamp":1773667198719,"version":"3.50.1"},"reference-count":21,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Isoniazid monotherapy has been the most widely used treatment for latent tuberculosis infection (LTBI). Although effective, it has been associated with poor adherence and a higher incidence of adverse events. The shorter duration of rifamycin-based regimens has become increasingly preferable. The one month of daily rifapentine plus isoniazid (1HP) has demonstrated low toxicity and higher completion rates in HIV-infected populations. This study aims to compare the completion rate and adverse events between the 1HP and daily isoniazid for 6 months (6H) regimens in the non-HIV adult population. Materials and Methods: Retrospective, observational, longitudinal study, followed at the National Reference Center for Tuberculosis (Lisbon, Portugal), from January 2024 to January 2025. Treatment-related symptoms and liver function were assessed throughout the treatment. Relevant hepatic toxicity was defined as aspartate transaminase (AST) and\/or alanine transaminase (ALT) &gt; 1.5 times the upper limit of normal (ULN). Results: A total of 90 and 74 patients were assigned to the 1HP and 6H groups, respectively. No significant differences were observed in the frequency of reported adverse symptoms between the 1HP and 6H groups (28.9% vs. 23.0%, p = 0.4). The 1HP regimen was associated with a significantly lower risk of relevant hepatic toxicity (4.6% vs. 32.9%, p &lt; 0.001) and a higher rate of treatment completion (97.8% vs. 67.6%, p &lt; 0.001). Adverse drug reactions were the leading cause of treatment discontinuation in both groups, with hepatic toxicity and gastrointestinal intolerance being the most frequent events. A therapeutic switch to rifampicin was required in 16.2% of patients receiving the 6H regimen, whereas no switch was needed in the 1HP group. Conclusions: The 1HP regimen was associated with a higher rate of treatment completion and lower hepatic toxicity with no significant differences in the reported adverse symptoms.<\/jats:p>","DOI":"10.3390\/medicina62030542","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:13:14Z","timestamp":1773659594000},"page":"542","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["One-Month Rifapentine\u2013Isoniazid Regimen Versus Six-Month Isoniazid Monotherapy for Latent Tuberculosis: Experience from a Reference Center"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3756-4080","authenticated-orcid":false,"given":"Joana Marques","family":"Sim\u00f5es","sequence":"first","affiliation":[{"name":"CDP Dr. Ribeiro Sanches, Pulmonary Department, Santa Maria Health Local Unit,  1649-045 Lisbon, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1714-5970","authenticated-orcid":false,"given":"Dalila","family":"Ferreira","sequence":"additional","affiliation":[{"name":"CDP Dr. Ribeiro Sanches, Pulmonary Department, Santa Maria Health Local Unit,  1649-045 Lisbon, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Mourato","sequence":"additional","affiliation":[{"name":"CDP Dr. Ribeiro Sanches, Pulmonary Department, Santa Maria Health Local Unit,  1649-045 Lisbon, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0530-0358","authenticated-orcid":false,"given":"Ana","family":"Pais","sequence":"additional","affiliation":[{"name":"CDP Dr. Ribeiro Sanches, Pulmonary Department, Santa Maria Health Local Unit,  1649-045 Lisbon, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Dias","sequence":"additional","affiliation":[{"name":"CDP Dr. Ribeiro Sanches, Pulmonary Department, Santa Maria Health Local Unit,  1649-045 Lisbon, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5883-0723","authenticated-orcid":false,"given":"Margarida","family":"Torres","sequence":"additional","affiliation":[{"name":"CDP Dr. Ribeiro Sanches, Pulmonary Department, Santa Maria Health Local Unit,  1649-045 Lisbon, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0701-3624","authenticated-orcid":false,"given":"Lu\u00eds","family":"Coelho","sequence":"additional","affiliation":[{"name":"CDP Dr. Ribeiro Sanches, Pulmonary Department, Santa Maria Health Local Unit,  1649-045 Lisbon, Portugal"},{"name":"Comprehensive Health Research Centre (CHRC), NOVA Medical School, NOVA University of Lisbon,  1099-085 Lisbon, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024). Global Tuberculosis Report 2024, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"World Health Organization (2020). WHO Consolidated Guidelines on Tuberculosis: Tuberculosis Preventive Treatment: Module 1: Prevention, World Health Organization.","DOI":"10.30978\/TB2021-2-86"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMcp2108501","article-title":"Latent tuberculosis infection","volume":"385","author":"Shah","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"16240","DOI":"10.1038\/s41598-023-43310-8","article-title":"Efficacy of Anti-Tuberculosis Drugs for the Treatment of Latent Tuberculosis Infection: A Systematic Review and Network Meta-Analysis","volume":"13","author":"Yoopetch","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/cid\/ciad246","article-title":"A Systematic Review and Meta-Analysis of Tuberculous Preventative Therapy Adverse Events","volume":"77","author":"Melnychuk","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"US Preventive Services Task Force, Mangione, C.M., Barry, M.J., Nicholson, W.K., Cabana, M., Chelmow, D., Coker, T.R., Davis, E.M., Donahue, K.E., and Ja\u00e9n, C.R. (2023). Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement. JAMA, 329, 1487\u20131494.","DOI":"10.1001\/jama.2023.4899"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/427802","article-title":"Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: A meta-analysis","volume":"40","author":"Ena","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMra1405427","article-title":"Latent mycobacterium tuberculosis Infection","volume":"372","author":"Getahun","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"k2738","DOI":"10.1136\/bmj.k2738","article-title":"Revisiting the timetable of tuberculosis","volume":"362","author":"Behr","year":"2018","journal-title":"BMJ"},{"key":"ref_13","unstructured":"World Health Organization (2023). Global Tuberculosis Report 2023, World Health Organization."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5588\/ijtld.21.0736","article-title":"The need for effective drugs for TB prevention: Set your goals high, and don\u2019t stop till you get there","volume":"26","author":"Lange","year":"2022","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2200388","DOI":"10.1183\/13993003.00388-2022","article-title":"Rifapentine access in Europe: Growing concerns over key tuberculosis treatment component","volume":"59","author":"Guglielmetti","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.5588\/ijtld.18.0168","article-title":"Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: A systematic review","volume":"22","author":"Hamada","year":"2018","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.cmi.2024.06.024","article-title":"One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: A randomized controlled trial","volume":"30","author":"Huang","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1902048","DOI":"10.1183\/13993003.02048-2019","article-title":"Treatment with isoniazid or rifampin for latent tuberculosis infection: Population-based study of hepatotoxicity, completion and costs","volume":"55","author":"Ronald","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/JCMA.0000000000000605","article-title":"Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis","volume":"84","author":"Tseng","year":"2021","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","article-title":"Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials","volume":"40","author":"Burman","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/MAJ.0b013e31814a586a","article-title":"Update on rifampin and rifabutin drug interactions","volume":"335","author":"Baciewicz","year":"2008","journal-title":"Am. J. Med. Sci."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/3\/542\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:13:20Z","timestamp":1773663200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/3\/542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["medicina62030542"],"URL":"https:\/\/doi.org\/10.3390\/medicina62030542","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]}}}